Should AbbVie (ABBV) Stock Get More Attention After Its Latest Pipeline Progress?
Should AbbVie (ABBV) Stock Get More Attention After Its Latest Pipeline Progress? Simply Wall St
Covered in this story
What has happened since
- AbbVie is down 1.2% since this was published.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on AbbVie
- UBS: at $276 · target $275 by Oct 2027 · Neutral via GuruFocus
- Bank of America: at $262 · target $289 by Sep 2027 · Buy via AOL.com
- Wolfe Research: at $263 · target $300 by Sep 2027 · Outperform via Yahoo Finance
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ABBV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on AbbVie →Dalsna Finance is currently tracking 48 stories mentioning AbbVie, the earliest published 16 May 2017.
Summary aggregated from Simply Wall St's public RSS feed. The full reporting belongs to Simply Wall St — please read it on their site.